103.18
-4.57 (-4.24%)
| Penutupan Terdahulu | 107.75 |
| Buka | 106.74 |
| Jumlah Dagangan | 489,319 |
| Purata Dagangan (3B) | 760,049 |
| Modal Pasaran | 5,992,571,904 |
| Harga / Pendapatan (P/E Ke hadapan) | 2.00 |
| Harga / Jualan (P/S) | 11.38 |
| Harga / Buku (P/B) | 8.94 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Apr 2026 |
| Margin Keuntungan | -30.57% |
| Margin Operasi (TTM) | -19.39% |
| EPS Cair (TTM) | -2.27 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 24.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.09% |
| Nisbah Semasa (MRQ) | 6.49 |
| Aliran Tunai Operasi (OCF TTM) | -45.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.66 M |
| Pulangan Atas Aset (ROA TTM) | -6.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | Glaukos Corporation | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.10 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.33% |
| % Dimiliki oleh Institusi | 101.71% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 160.00 (Stifel, 55.07%) | Beli |
| Median | 135.00 (30.84%) | |
| Rendah | 127.00 (Needham, 23.09%) | Beli |
| Purata | 139.60 (35.30%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 119.92 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 18 Feb 2026 | 131.00 (26.96%) | Beli | 121.00 |
| 28 Jan 2026 | 131.00 (26.96%) | Beli | 123.94 | |
| Needham | 18 Feb 2026 | 127.00 (23.09%) | Beli | 121.00 |
| 14 Jan 2026 | 125.00 (21.15%) | Beli | 104.43 | |
| Wells Fargo | 18 Feb 2026 | 135.00 (30.84%) | Beli | 121.00 |
| Stifel | 22 Jan 2026 | 160.00 (55.07%) | Beli | 125.90 |
| Stephens & Co. | 02 Jan 2026 | 145.00 (40.53%) | Beli | 110.72 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BURNS THOMAS WILLIAM | - | 98.94 | -2,801 | -277,131 |
| GILLIAM JOSEPH E | - | 98.94 | -1,189 | -117,640 |
| NAVRATIL TOMAS | - | 98.94 | -1,989 | -196,792 |
| THURMAN ALEX R. | - | 100.94 | -1,239 | -125,080 |
| Jumlah Keseluruhan Kuantiti Bersih | -7,218 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -716,643 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 99.61 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| THURMAN ALEX R. | Pegawai | 17 Mar 2026 | Jual automatik (-) | 625 | 102.93 | 64,331 |
| GILLIAM JOSEPH E | Pegawai | 16 Mar 2026 | Dibuang (-) | 1,189 | 98.94 | 117,640 |
| BURNS THOMAS WILLIAM | Pegawai | 16 Mar 2026 | Dibuang (-) | 2,801 | 98.94 | 277,131 |
| NAVRATIL TOMAS | Pegawai | 16 Mar 2026 | Dibuang (-) | 958 | 98.94 | 94,785 |
| NAVRATIL TOMAS | Pegawai | 16 Mar 2026 | Jual automatik (-) | 1,031 | 98.94 | 102,007 |
| THURMAN ALEX R. | Pegawai | 16 Mar 2026 | Dibuang (-) | 614 | 98.94 | 60,749 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Jan 2026 | Pengumuman | Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR |
| 20 Jan 2026 | Pengumuman | Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 |
| 13 Jan 2026 | Pengumuman | Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |